Drugs / Anacetrapib
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01122667 | Jun 2010 → Jun 2011 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01114490 | May → Jul 2010 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00990808 | Nov 2009 → Jun 2011 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00565006 | Jul → Sep 2006 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00565292 | Jul → Aug 2006 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00977288 | Sep 2009 → Mar 2010 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00325455 | Jun 2006 → Feb 2007 | hyperlipidemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT01841684 | Jun 2013 → Jun 2014 | homozygous familial hypercholesterolemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01860729 | May 2013 → May 2015 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01824238 | May 2013 → May 2014 | familial hypercholesterolemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01760460 | Mar 2013 → Mar 2015 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01717300 | Nov 2012 → Oct 2014 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01524289 | Feb 2012 → Feb 2014 | familial hypercholesterolemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01252953 | Jun 2011 → Jan 2017 overdue | atherosclerotic cardiovascular disease | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00685776 | Mar 2008 → Jul 2009 | coronary artery disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anacetrapib | “Anacetrapib (MK-0859) is a CETP inhibitor currently under development.” PMID 18068514 ↗ Dec 2007 |
| Known as | ANA | “We investigated the effects of the cholesteryl ester (CE) transfer protein inhibitor anacetrapib (ANA) on plasma lipids, lipoprotein subfraction concentrations, and lipoprotein...” PMID 22180633 ↗ Dec 20111“This study evaluated the effects of anacetrapib (ANA) on lipids and safety when administered as monotherapy or in combination with atorvastatin (ATV) in Japanese patients...” PMID 23958252 ↗ Jun 2013 |
| Known as | MK-0859 | “Anacetrapib (MK-0859) is a CETP inhibitor currently under development.” PMID 18068514 ↗ Dec 20074“single dose administration of anacetrapib (MK0859) 100 mg oral tablet” NCT01114490 ↗ “single dose administration of anacetrapib (MK0859) 100 mg oral tablet” NCT01122667 ↗ “transfer protein inhibitor anacetrapib (MK-0859) in patients” PMID 21982664 ↗ Sep 2011 |
| Action | Inhibit | “Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor” PMID 24737712 ↗ Apr 2014 |
| Modality | Small molecule | — CHEMBL1800807 ↗ |
| Route | Oral | “received anacetrapib doses of 0, 10, 40, 150, or 300 mg orally once a day with a meal for 28 days.” PMID 18068514 ↗ Dec 2007 |
| Target | CETP | “anacetrapib, a CETP (cholesteryl ester transfer protein) inhibitor” PMID 28729361 ↗ Jul 2017 |